Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug in Moderately to Severely Active Ulcerative Colitis (SUNSCAPE-2)
NCT07185009Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Jan 2026
- Primary completion
- Sep 2028
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of duvakitug in ulcerative colitis (UC) (4 arms), sponsored by Sanofi. Primary endpoint: Clinical Remission by modified Mayo Score (mMS) at 40 weeks. Started Jan 2026; status: recruiting.
02
Drugs
duvakitug
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07185009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185009.